Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease
Sponsor: Asceneuron Pty Ltd.
Terminated
Delays with sites, identifying/enrolling patients, impact of COVID, staffing, and duration
Other terminated trials from Asceneuron Pty Ltd.
More terminations from Asceneuron Pty Ltd.
This PHASE1 trial investigates Alzheimer Disease and is currently terminated or withdrawn. Asceneuron Pty Ltd. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jul 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Asceneuron Pty Ltd.
- Asceneuron S.A.
- Neuroscience Trials Australia
For direct contact, visit the study record on ClinicalTrials.gov .